Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Valuable Targets
6 min read
Advancements in Clinical Research on CDK5 Inhibitors
15 September 2023
CDK5, or cyclin-dependent kinase 5, is a crucial enzyme found in the human body that plays a significant role in various physiological processes.
Drug Insights
4 min read
Pharmaceutical Insights: Silodosin's R&D Progress
15 September 2023
This article summarized the latest R&D progress of Silodosin, the Mechanism of Action for Silodosin, and the drug target R&D trends for Silodosin.
Latest Hotspot
3 min read
Bristol Myers Squibb's trial LPA1 Antagonist reduced lung function decline in Progressive Pulmonary Fibrosis patients in a phase 2 study
15 September 2023
Bristol Myers Squibb's experimental LPA1 Antagonist showed promising results in reducing the rate of lung function decline in the Progressive Pulmonary Fibrosis group in a phase 2 clinical trial.
Drug Insights
4 min read
Exploring Secretin's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
15 September 2023
This article summarized the latest R&D progress of Secretin, the Mechanism of Action for Secretin, and the drug target R&D trends for Secretin.
Valuable Targets
5 min read
CDK4 Inhibitor - A Highly Noticed Breast Cancer Treatment Drug
15 September 2023
CDK4, or cyclin-dependent kinase 4, is a crucial protein involved in cell cycle regulation in the human body.
Drug Insights
4 min read
Decoding Riluzole: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
15 September 2023
This article summarized the latest R&D progress of Riluzole, the Mechanism of Action for Riluzole, and the drug target R&D trends for Riluzole.
Latest Hotspot
3 min read
Promising results were noted in Phase 1b of the TROPION-Lung04 trial, combining Datopotamab Deruxtecan and Durvalumab for Non-Small Cell Lung Cancer
15 September 2023
Promising clinical responses were observed in TROPION-Lung04's Phase 1b Trial with a combination of Datopotamab Deruxtecan and Durvalumab with Non-Small Cell Lung Cancer.
Drug Insights
4 min read
Deep Scientific Insights on Ranolazine's R&D Progress,Drug Target
15 September 2023
This article summarized the latest R&D progress of Ranolazine, the Mechanism of Action for Ranolazine, and the drug target R&D trends for Ranolazine.
Valuable Targets
7 min read
CDK2 Inhibitor——Important Regulator of Cell Cycle Control
15 September 2023
CDK2, or cyclin-dependent kinase 2, is a crucial protein involved in cell cycle regulation in the human body.
Drug Insights
4 min read
An In-depth Analysis of Ramelteon's R&D Progress
15 September 2023
This article summarized the latest R&D progress of Ramelteon, the Mechanism of Action for Ramelteon, and the drug target R&D trends for Ramelteon.
Latest Hotspot
4 min read
The HERTHENA-Lung01 Phase 2 Trial demonstrated significant, lasting effects of Patritumab Deruxtecan in non-small cell lung cancer patients
15 September 2023
The HERTHENA-Lung01 Phase 2 Trial showed that Patritumab Deruxtecan brought about meaningful and durable effects in Patients with non-small cell lung cancer.
Drug Insights
4 min read
Perphenazine: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
15 September 2023
This article summarized the latest R&D progress of Perphenazine, the Mechanism of Action for Perphenazine, and the drug target R&D trends for Perphenazine.